Rich Tyvin, Zhao Fengmin, Cruciani Ricardo A, Cella David, Manola Judith, Fisch Michael J
Hampton University Proton Therapy Institute, Hampton, VA.
Dana-Farber Cancer Institute, Boston, MA.
Cancer Manag Res. 2017 Jan 31;9:1-10. doi: 10.2147/CMAR.S115835. eCollection 2017.
The biology of fatigue and depression in cancer patients is poorly understood. Hypotheses regarding cytokines and growth factors related to sickness behavior and disruption of circadian signaling have been proposed.
We prospectively examined proinflammatory cytokines (e.g., sickness behavior model) and epidermal growth factor receptor (EGFR) ligands (e.g., circadian disruption model) in the serum of cancer patients enrolled in a clinical trial testing levocarnitine for fatigue.
Serum samples were collected at baseline and week 4. Cytokine/growth factor analyses were performed with a Luminex analyzer. The Brief Fatigue Index and the Center for Epidemiologic Studies Depression Index were used to measure fatigue and depression severity. The association between cytokine and symptoms was examined using logistic models.
Among 101 analyzable patients, all ten cytokines/growth factors examined were highly elevated at baseline and all significantly decreased at week 4 (<0.001) regardless of treatment intervention. At baseline, the odds of severe fatigue significantly increased for patients with higher level of interleukin-1 receptor antagonist (IL-1Ra), whereas patients with higher levels of IL-1Ra, tumor necrosis factor-α, interleukin (IL)-6, IL-8, interferon-γ, transforming growth factor α, and vascular endothelial growth factor had higher odds of severe depression. At week 4, fatigue (=0.023) and depression (=0.007) responders had less decrease in IL-1 level than the corresponding non-responders.
In this correlative analysis of a fatigue clinical trial, levels of fatigue were significantly associated with levels of IL-1 and IL-1Ra. Circadian-signaling pathways related to EGFR signaling were correlated with depression as were other cytokines. A major placebo effect was associated with a global decrease in cytokine and growth factors. These data provide further basis for testing hypotheses regarding the mechanisms of fatigue and depression in cancer patients.
癌症患者疲劳和抑郁的生物学机制尚未得到充分理解。关于细胞因子和生长因子与疾病行为及昼夜节律信号紊乱的假说已被提出。
我们对参加左卡尼汀治疗疲劳临床试验的癌症患者血清中的促炎细胞因子(如疾病行为模型)和表皮生长因子受体(EGFR)配体(如昼夜节律紊乱模型)进行了前瞻性研究。
在基线和第4周采集血清样本。使用Luminex分析仪进行细胞因子/生长因子分析。采用简明疲劳指数和流行病学研究中心抑郁指数来测量疲劳和抑郁的严重程度。使用逻辑模型检查细胞因子与症状之间的关联。
在101例可分析的患者中,无论治疗干预如何,所检测的全部10种细胞因子/生长因子在基线时均显著升高,在第4周时均显著下降(<0.001)。在基线时,白细胞介素-1受体拮抗剂(IL-1Ra)水平较高的患者出现严重疲劳的几率显著增加,而IL-1Ra、肿瘤坏死因子-α、白细胞介素(IL)-6、IL-8、干扰素-γ、转化生长因子α和血管内皮生长因子水平较高的患者出现严重抑郁的几率更高。在第4周时,疲劳(=0.023)和抑郁(=0.007)的缓解者IL-1水平的下降幅度小于相应的未缓解者。
在这项疲劳临床试验的相关性分析中,疲劳程度与IL-1和IL-1Ra水平显著相关。与EGFR信号相关的昼夜节律信号通路与抑郁相关,其他细胞因子也如此。主要的安慰剂效应与细胞因子和生长因子的整体下降有关。这些数据为检验关于癌症患者疲劳和抑郁机制的假说提供了进一步的依据。